Home Fluorides 191330-56-0
191330-56-0,MFCD13185925
Catalog No.:AA0074RF

191330-56-0 | (3R,4S)-1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-4-(4-hydroxyphenyl)azetidin-2-one

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$88.00   $62.00
- +
5mg
98%
in stock  
$181.00   $127.00
- +
10mg
98%
in stock  
$250.00   $175.00
- +
25mg
98%
in stock  
$481.00   $337.00
- +
50mg
98%
in stock  
$820.00   $574.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA0074RF
Chemical Name:
(3R,4S)-1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-4-(4-hydroxyphenyl)azetidin-2-one
CAS Number:
191330-56-0
Molecular Formula:
C24H19F2NO3
Molecular Weight:
407.4094
MDL Number:
MFCD13185925
SMILES:
Oc1ccc(cc1)[C@@H]1[C@@H](CCC(=O)c2ccc(cc2)F)C(=O)N1c1ccc(cc1)F
Properties
Computed Properties
 
Complexity:
606  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
6  
XLogP3:
4.1  

Downstream Synthesis Route

[1]Rosenblum,StuartB.;Huynh,Tram;Afonso,Adriano;DavisJr.,HarryR.;Yumibe,Nathan;Clader,JohnW.;Burnett,DuaneA.[JournalofMedicinalChemistry,1998,vol.41,#6,p.973-980]

[2]CurrentPatentAssignee:IND-SWIFTLABORATORIESLIMITED-WO2008/96372,2008,A2Locationinpatent:Page/Pagecolumn21-22

[1]CurrentPatentAssignee:CHANGZHOUPHARMACEUTICALFACTORYCO.,LTD.-CN107129452,2017,ALocationinpatent:Paragraph0007;0010

[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn18

[3]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn17

[4]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn18

[5]CurrentPatentAssignee:MEDICHEM,S.A.-US2009/227786,2009,A1Locationinpatent:Page/Pagecolumn18

[6]Wu;Wong;Chen;Ding[JournalofOrganicChemistry,1999,vol.64,#10,p.3714-3718]

[7]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn16

[8]CurrentPatentAssignee:MEDICHEM,S.A.-US2010/168414,2010,A1Locationinpatent:Page/Pagecolumn6

[9]Locationinpatent:experimentalpartKyslikova,Eva;Babiak,Peter;Maresova,Helena;Palyzova,Andrea;Hajicek,Josef;Kyslik,Pavel[JournalofMolecularCatalysisB:Enzymatic,2010,vol.67,#3-4,p.266-270]

[10]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn18

[11]CurrentPatentAssignee:CHINANATIONALPHARMACEUTICALGROUPCORPORATION-CN107118144,2017,ALocationinpatent:Paragraph0035-0049

[12]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn17

[13]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn17

[14]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2008/106900,2008,A1Locationinpatent:Page/Pagecolumn9

[15]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn18

[16]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn16-17

[17]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2008/151324,2008,A1Locationinpatent:Page/Pagecolumn17

[18]CurrentPatentAssignee:SUNPHARMACEUTICALINDUSTRIESLIMITED-WO2005/66120,2005,A2Locationinpatent:Page/Pagecolumn17-18

[19]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/30721,2007,A2Locationinpatent:Page/Pagecolumn28

[20]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/30721,2007,A2Locationinpatent:Page/Pagecolumn30

[21]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[22]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76;78

[23]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[24]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[25]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[26]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[27]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[28]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[29]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[30]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[31]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[32]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[33]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2008/106900,2008,A1Locationinpatent:Page/Pagecolumn12-13

[34]CurrentPatentAssignee:KRKADDNOVOMESTO-EP1953140,2008,A1Locationinpatent:Page/Pagecolumn19

[35]Ren,Yun;Duan,Yan-Jun;Li,Ren-Jun;Deng,Yong;Hai,Li;Wu,Yong[ChineseChemicalLetters,2014,vol.25,#8,p.1157-1160]

191330-56-0   
(3R,4R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one 
  163222-33-1 

[1]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[3]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[4]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[5]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[6]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[7]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[8]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[9]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[10]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[11]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76

[12]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[13]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[14]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[15]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[16]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[17]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[18]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[19]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[20]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[21]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[22]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2007/120824,2007,A2Locationinpatent:Page/Pagecolumn76-77

[1]JournalofOrganicChemistry,1999,vol.64,p.3714-3718

[1]JournalofMedicinalChemistry,1998,vol.41,p.973-980

Literature

Title: Yijun Zhu, et al. Efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe. Synthetic Communications. 2016, 46:20, 1687-1693.

Title: Lee DH, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med. 2016 Sep 12;99:520-532.

Title: Chang E, et al. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World J Gastroenterol. 2015 Jul 7;21(25):7754-63.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:191330-56-0 Molecular Formula|191330-56-0 MDL|191330-56-0 SMILES|191330-56-0 (3R,4S)-1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-4-(4-hydroxyphenyl)azetidin-2-one